前列地尔药理学研究进展及在呼吸系统疾病中的应用  

Pharmacological research advance of alprostadil and its application in respiratory system diseases

作　　者：刘春云 刘永平[2] 龚享文 

机构地区：[1]赣州市第五人民医院呼吸科,江西赣州341000 [2]湖南中医药大学生理学教研室,湖南长沙410208

出　　处：《中国新药与临床杂志》2012年第11期648-651,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：前列地尔即前列腺素E_1(PGE_1),具有扩血管、抗炎、抗血小板聚集、保护血管内皮细胞、防止动脉粥样硬化等作用。其制剂PGE_1脂质载体(Lipo-PGE_1)的开发,使其在临床上应用更广泛。本文概述前列地尔的药理学作用机制及其在肺动脉高压、支气管哮喘、毛细支气管炎及慢性肺心病等呼吸系统疾病中的应用现状。Alprostadil （prostaglandin E1, PGE1） has many pharmacological actions, such as vasodila- tion, anti-inflammatory, anti- platelet aggregation, protection of vascular endothelial ceils, prevention of athe- rosclerosis, and so on. As the development of its formulations lipid carrier （Lipo-PGE1）, alprostadil has been used more widely in clinic. Pharmacological mechanism of alprostadil and its application status in pulmonary hypertension, bronchial asthma, bronchiolitis and chronic pulmonary heart disease are reviewed in this paper.

关 键 词：前列地尔 呼吸系统 疾病 

分 类 号：R56[医药卫生—呼吸系统]